Intelligence · Patents
Patents expiring in 2042
Annual patent cliff calendar for 2042 — US pharmaceutical patents by expiration date.
- Patents
- 1,738
Quick answer
1,738 indexed pharmaceutical patents have expiration dates in 2042. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 11357801
Methods for treating autism spectrum disorder and associated symptoms
granted -
US 11357770
Method of treating immunoglobulin light chain amyloidosis
granted -
US 11357777
Use of sGC stimulators for the treatment of nonalcoholic steatohepatitis (NASH)
granted -
US 11357736
Detoxification using nanoparticles
granted -
US 11357782
Treprostinil administration by inhalation
granted -
US 11357710
Solid mask and preparation method therefor
granted -
US 11357725
Delivery of agents using metastable liposomes
granted -
US 11357743
Ketamine and propofol admixture
granted -
US 11357783
Conjugate of finasteride with peptide
granted -
US 11357830
Nano-scale delivery device and uses thereof
granted -
US 11357817
Immunoproteasome inhibitor
granted -
US 11357870
Codon optimized REP1 genes and uses thereof
granted -
US 11358931
Selective androgen receptor modulators (SARMs) and uses thereof
granted -
US 11357872
Imaging neurotransmitters in vivo using functionalized carbon nanotubes
granted -
US 11358947
Substituted 2-acylamino-cycloalkylthiophene-3-carboxylic acid arylamides as inhibitors of calcium-activated chloride channel TMEM16A
granted -
US 11357832
Treatment of cognitive impairment of hunter syndrome by intrathecal delivery of iduronate-2-sulfatase
granted -
US 11357854
Pharmaceutical compositions comprising meloxicam
granted -
US 11358940
K-Ras modulators
granted -
US 11357842
PD-L1 targeting DNA vaccine for cancer immunotherapy
granted -
US 11359246
Treatment of obesity with G-protein coupled receptor 75 (GPR75) inhibitors
granted -
US 11359204
Chimeric antigen receptors targeting B-cell maturation antigen
granted -
US 11358977
Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
granted -
US 11358991
Heme sequesting peptides and uses therefor
granted -
US 11359195
Method for identifying antibiotic targets
granted -
US 11357727
Manufacturing of bupivacaine multivesicular liposomes
granted -
US 11358965
EGFR dimer disruptors and use of the same
granted -
US 11357839
Brachyury protein, non-poxvirus non-yeast vectors encoding Brachyury protein, and their use
granted -
US 11357742
Methods for treating cancer
granted -
US 11359024
Anti-AVB8 antibodies and compositions and uses thereof
granted -
US 11358932
N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors
granted -
US 11357860
Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells
granted -
US 11357841
Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
granted -
US 11357795
Combination immunotherapies for treatment of cancer
granted -
US 11357759
Composition including ADAM9 inhibitor and the use thereof
granted -
US 11364260
Methods and compositions for administration of iron
granted -
US 11364261
Alleviating common cold and influenza symptoms with molecular hydrogen
granted -
US 11364293
Compositions and methods for making and using thermostable immunogenic formulations with increased compatibility of use as vaccines against one or more pathogens
granted -
US 11365183
Eicosanoid derivatives
granted -
US 11364202
Solid forms of cannabidiol and uses thereof
granted -
US 11364240
Pyruvate kinase activators for use in treating blood disorders
granted -
US 11364215
GHB formulation and method for its manufacture
granted -
US 11364227
Sphingosine kinase 2 inhibitor for treating coronavirus infection
granted -
US 11364228
Gaboxadol for therapeutic treatment of 1p36 deletion syndrome
granted -
US 11364309
Neuronal enhancers
granted -
US 11364304
Crosslinked micellar spherical nucleic acids
granted -
US 11365221
Compositions and methods for treating autoimmune and inflammatory disorders
granted -
US 11364300
C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors
granted -
US 11364308
Adeno-associated virus variant capsids and methods of use thereof
granted
Frequently asked questions
How many pharma patents expire in 2042?
1,738 published patents in our USPTO index have expiration dates falling in calendar year 2042.